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those 45–64s, and 30% of those 65. The mean annual
cost was $2,200; with 0 comorbidities: $1,200; with 1:
$2,000; with 1: $5,200. The R2 for the regression with-
out complications 0.0085 (0.85% of log charges ex-
plained by age and gender). The R2 with complications
was 0.1121 (11% explained by age, gender and compli-
cations). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 13 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Complications of Type 2 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 2 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient ser-
vices were tallied over CY 1997. Members were classi-
fied: (1) as having 0,1, or 1 complications (nephropathy,
retinopathy, neuropathy, or CAD), and (2) by age: 18,
18–44, 45–64, or 65. A regression of age and gender
on ln(charges) was compared to a regression of age, gen-
der, and complications. RESULTS: Over 124,000 mem-
bers were included in the study, about half male and fe-
male. About 85% were 45 or older. Approximately
82,000 (66%) had 0 comorbidities, 32,500 (26%) had 1,
and 10,000 (8%) had 1; 92% of those 18 had 0 co-
morbidities; 83% of those 18–44 did; 70% of those 45–
64 did; 52% of those 65 did. Similarly, 0.4% of those
18 had 1 comorbidity; 2.5% of those 18–44s, 6.6%
of those 45–64s, and 13% of those 65. The mean an-
nual cost was $820; with 0 comorbidities: $575; with 1:
$1,000; with 1: $2,300. The R2 for the regression with-
out complications 0.0059 (0.6% of log charges explained
by age and gender). The R2 with complications was
0.0487 (5% explained by age, gender and complica-
tions). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 8 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Diabetic foot ulcers are a common problem and result in
more than 50,000 lower extremity amputations each
year in the United States. Studies have suggested that be-
tween 25% and 50% of costs related to inpatient diabe-
tes care may be directly attributable to the diabetic foot.
OBJECTIVE: To compare the cost-effectiveness of treat-
ment with standard Wound Care Center (WCC) care
with treatment with Platelet Releasate (PR), an autolo-
gous product that provides concentrated platelet-derived
growth factor directly to the wound. METHODS: Our
analysis is based on effectiveness data from a database
created by Curative Health Services that includes data on
over 26,500 patients with diabetic neuropathic foot ul-
cers. Effectiveness was assessed as percentage of ulcers
healed at 32 weeks. Cost estimates were derived from the
Medicare Resource-Based Relative Value Scale. A sensi-
tivity analysis was conducted by adjusting several of the
variables associated with the cost-effectiveness equation.
RESULTS: Baseline cost for 32 weeks of therapy was
$2880.01 for WCC care (n  14,735) and $5680.01 for
PR (n  4701). Baseline effectiveness (with 95% confi-
dence intervals) for WCC and PR care were 38.0 (37.2,
38.8) and 48.4 (46.9, 49.8) respectively. The cost-effec-
tiveness ratio for PR vs WCC care was 269.23. This ratio
represents the marginal cost (in 1999 US dollars) of in-
creasing the chance of healing at 32 weeks by 1% by us-
ing PR rather than WCC care. CONCLUSIONS: While
PR is more expensive than WCC care, it does provide a
27% improvement in baseline healing at 32 weeks, and
the incremental increased cost must be weighed against
the substantial economic and psychological impact of
lower extremity amputation.
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Cost savings associated with detection and treatment of
diabetic eye disease has been well documented. However,
the cost-effectiveness of retinopathy screening in pediat-
ric patients with type I diabetes mellitus remains unclear.
In 1998, the Academy of Pediatrics released a new policy
regarding the ophthalmologic examination schedule for
